Dechra Pharmaceuticals PLC Director/PDMR Shareholding (1712R)
September 19 2017 - 5:30AM
UK Regulatory
TIDMDPH
RNS Number : 1712R
Dechra Pharmaceuticals PLC
19 September 2017
19 September 2017
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 19 September 2017,
the following PDMRs exercised nil cost options over ordinary shares
of 1p each in the Company. The options were granted to them on 15
September 2014 pursuant to the Dechra Pharmaceuticals PLC Long Term
Incentive Plan (the LTIP). The exercise of the options was subject
to the achievement of performance conditions which vested at 100%
of the total award.
Name Capacity Options Exercised Total beneficial Percentage
shareholding of issued
following share
this announcement capital
Ian Page Director 115,334 792,142 0.848%
Tony
Griffin Director 29,937 94,257 0.101%
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- ----------------------------------------------------------------
a) Name Ian Page
--- ----------------------------- ---------------------------------
2. Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Director/PDMR
--- ----------------------------- ---------------------------------
b) Initial notification/ Initial Notification
amendment
--- ----------------------------- ---------------------------------
3. Details of the Issuer
--- ----------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ----------------------------- ---------------------------------
b) LEI code N/A
--- ----------------------------- ---------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument
Identification ISIN: GB0009633180
code
--- ----------------------------- ---------------------------------
b) Nature of Exercise of 115,334 options
the transaction under the Company's Long Term
Incentive Plan
--- ----------------------------- ---------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
GBPNil Cost 115,334
--- ----------------------------- ------------------ -------------
d) Aggregated
information
* Aggregate volume N/A
* Price
--- ----------------------------- ---------------------------------
e) Date of the 2017.09.15
transaction
--- ----------------------------- ---------------------------------
f) Place of the Outside a trading venue
transaction
--- ----------------------------- ---------------------------------
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- -----------------------------------------------------------------
a) Name Tony Griffin
--- ------------------------------ ---------------------------------
2. Reason for the notification
--- -----------------------------------------------------------------
a) Position/status Director/PDMR
--- ------------------------------ ---------------------------------
b) Initial notification/ Initial Notification
amendment
--- ------------------------------ ---------------------------------
3. Details of the Issuer
--- -----------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ------------------------------ ---------------------------------
b) LEI code N/A
--- ------------------------------ ---------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument
Identification ISIN: GB009633180
code
--- ------------------------------ ---------------------------------
b) Nature of Exercise of 29,937 options
the transaction under the Company's Long Term
Incentive Plan
--- ------------------------------ ---------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
GBPnil 29,937
--- ------------------------------ --------------- ----------------
d) Aggregated
information
* Aggregate volume N/A
* Price
--- ------------------------------ ---------------------------------
e) Date of the 2017.09.15
transaction
--- ------------------------------ ---------------------------------
f) Place of the Outside a trading venue
transaction
--- ------------------------------ ---------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKCDBKBKDCCD
(END) Dow Jones Newswires
September 19, 2017 06:30 ET (10:30 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024